News | January 03, 2024
WuXi XDC partners with IntoCell to accelerate ADC discovery and development
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Subscribe To Our Newsletter & Stay Updated
